| Document |
Document Title |
|
WO/2022/101603A1 |
This invention particularly relates to trifunctional PROTACs of formula I as described herein which bind to a protein within the Bromo- and Extra-Terminal (BET) family of proteins, and especially to PROTACs including small molecule E3 ub...
|
|
WO/2022/099117A1 |
The present disclosure provides bifunctional compounds comprising a target protein binding moiety and a E3 ubiquitin ligase binding moiety, and associated methods of use.
|
|
WO/2022/088679A1 |
The present invention belongs to the field of multidisciplinary intersections of chemistry, pharmaceuticals, medicine, etc., and more particularly relates to a method for removing tumor stem cells, an anti-cancer drug, a drug delivery sy...
|
|
WO/2022/088460A1 |
The present invention relates to an organic compound, an organic electroluminescent material and an organic electroluminescent element. The structural formula of the compound is shown in formula (I). When the organic compound of the pres...
|
|
WO/2022/092141A1 |
The present invention provides: a compound, or a pharmaceutically acceptable salt thereof, having an antiviral activity and represented by formula (I); and a pharmaceutical composition containing the same. (In the formula, the broken lin...
|
|
WO/2022/090481A1 |
The present invention encompasses compounds of formula (I), wherein the groups R1 to R4 and X1 to X5 have the meanings given in the claims and specification, their use as inhibitors of mutant EGFR, pharmaceutical compositions which conta...
|
|
WO/2022/089389A1 |
The present invention relates to the field of pharmaceutical chemistry, and relates to a heterocyclic compound, a preparation method therefor, a pharmaceutical composition thereof and an application thereof. In particular, the present in...
|
|
WO/2022/089514A1 |
A polycyclic bioregulator, a preparation method therefor and an application thereof. In particular, the present invention relates to a compound represented by general formula (II) or a stereoisomer thereof, a preparation method therefor,...
|
|
WO/2022/091799A1 |
The present invention provides a photoelectric conversion element, an imaging element, an optical sensor, and a compound that provide high photoelectric conversion efficiency. This photoelectric conversion element comprises, in this orde...
|
|
WO/2022/078250A1 |
Provided is an organic compound. The organic compound has a structure represented by formula (I): wherein each of X 1 to X 4 independently represents N or CR; L 1 represents a single bond or an aryl residue; L 2 represents a single bond ...
|
|
WO/2022/078971A1 |
The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of diseases, disorders and or abnormality associated with misfolding of Tau protein and/or pathological aggregat...
|
|
WO/2022/078414A1 |
Provided are compounds of Formula (I) and pharmaceutically acceptable salts and compositions thereof, which are useful for treating cancers and related conditions.
|
|
WO/2022/081758A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
|
|
WO/2022/075240A1 |
The present invention provides compounds that have a Pim-1 inhibitory activity. The present invention provides, inter alia, compounds with formula [I] and their pharmaceutically acceptable salts, pharmaceutical compositions containing ...
|
|
WO/2022/076831A2 |
This disclosure provides chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit epidermal growth factor receptor (EGFR, ERBB1) an...
|
|
WO/2022/076622A2 |
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having core structure (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseas...
|
|
WO/2022/071428A1 |
The present invention provides a compound having an excellent control effect against harmful arthropods. The compound represented in expression (I) (in the expression, Q represents a group indicated by Q1, ● represents the binding site...
|
|
WO/2022/069357A1 |
The present invention relates to a crystalline form of selpercatinib and to a process for its preparation. Furthermore, the invention relates to a pharmaceutical composition comprising the crystalline form of selpercatinib of the present...
|
|
WO/2022/068921A1 |
A quinazoline compound as shown in formula I, and a pharmaceutically acceptable salt, solvate, prodrug, metabolite or isotopic compound thereof, having a good inhibiting effect on a KRAS mutant protein.
|
|
WO/2022/063303A1 |
The present invention belongs to the technical field of medicines, and relates to a class of fused ring compounds, and the preparation and use thereof. Test results show that the compounds can significantly inhibit the ATM kinase activit...
|
|
WO/2022/063128A1 |
An aromatic ring or arylheterocyclic pyridone compound, pharmaceutical compositions, and a use thereof, in particular an aromatic ring or arylheterocyclic pyridone compound represented by formula (I), or pharmaceutically acceptable salts...
|
|
WO/2022/062597A1 |
A thermally activated delayed fluorescence material and the use thereof. The thermally activated delayed fluorescence material has a diquinoxaline structure, is new in structure, has good photoelectric properties, and is suitable as a li...
|
|
WO/2022/066734A1 |
This disclosure provides chemical entities of Formula (I) (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/ or cocrystal, and/or drug combination of the compound) that inhibit epidermal growth factor receptor ...
|
|
WO/2022/059778A1 |
The present invention provides a compound that has an inhibitory effect on DYRK and is represented by general formula (I) (in the formula, A1, A2, L, R1, and R2 are as described in the specification).
|
|
WO/2022/060836A1 |
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
|
|
WO/2022/058344A1 |
The present invention covers Pyrido[2,3‐d]pyrimidin‐4‐amines compounds of general formula (I): in which R1, R2, R3, A, x and y are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing ...
|
|
WO/2022/061251A1 |
Disclosed are compounds of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer, or a deuterated analog thereof, wherein: R1, R2, R3, X, and Z are as described in any of the embodiments described in thi...
|
|
WO/2022/059779A1 |
The invention of the present application provides an amine derivative having a DYRK-inhibiting activity and represented by formula (1) (see the description with respect to A1, A2, L1, L2, X, Z, R1 and R4 in the formula), or a pharmaceuti...
|
|
WO/2022/058920A1 |
A compound of Formula (I), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with casein kinase 1 delta (CSN...
|
|
WO/2022/052924A1 |
A preparation method for a class of nitrogen-containing fused ring compounds and a use thereof, specifically, a nitrogen-containing fused ring compound represented by general formula I, or a pharmaceutically acceptable salt thereof, or a...
|
|
WO/2022/053628A1 |
The present invention relates to a compound of formula (I). It also relates to a pharmaceutical composition comprising at least one compound of formula (I) and at least one pharmaceutically acceptable support. Finally, it relates to the ...
|
|
WO/2022/052958A1 |
This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
|
|
WO/2022/056307A1 |
The present invention relates to crystalline forms of a KRas G12C inhibitor and salt thereof. In particular, the present invention relates to crystalline forms of the KRas GT2C inhibitor 2-[(2S)- 4-[7-(8-chloro-l-naphthyI)-2-[[(2S)-l-met...
|
|
WO/2022/048665A1 |
This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
|
|
WO/2022/048675A1 |
Provided are a new crystal form of Risdiplam (referred to as "compound I") and a preparation method therefor, a pharmaceutical composition containing the crystal form, and a use of the crystal form in preparation of a drug for treating s...
|
|
WO/2022/049141A1 |
Compounds of the formula (I) wherein G1, G2, X, R1, R2 R3, and R4 are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these composi...
|
|
WO/2022/049144A1 |
Compounds of the formula (I) wherein G1, G2, X, R2 and Q are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compositions, an...
|
|
WO/2022/051765A1 |
Disclosed herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and their pharmaceutical compositions: The compounds are useful as agonists of Stimulator of Interferon Genes (STING), such as in a method of treat...
|
|
WO/2022/051317A1 |
Provided herein are processes for synthesizing Mcl-1 inhibitors and intermediates such as compound Y that can be used to prepare them where the variable R1 is as defined herein. In particular, provided herein are processes for synthesizi...
|
|
WO/2022/046690A1 |
Provided herein are solid dispersions comprising AMG 397, methods of preparing the solid dispersion, and pharmaceutical formulations comprising AMG 397.
|
|
WO/2022/042331A1 |
The present invention relates to a heterocyclic compound, and a preparation method therefor and the use thereof. Specifically, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, an ester, a ...
|
|
WO/2022/043865A1 |
An object of the present invention is to provide a crystal of compound 1, which is useful as an antitumor agent, the crystal being stable, excellent in oral absorbability, highly chemically pure, and suitable for mass production. The pre...
|
|
WO/2022/047031A1 |
The disclosure provides at least one entity chosen from compounds of Formula I, a tautomer thereof, a deuterated derivative of that compound or tautomer, and a pharmaceutically acceptable salt of any of the foregoing, compositions compri...
|
|
WO/2022/041615A1 |
The present invention relates to the field of pesticides, and specifically relates to a substituted phenylpyrazoline derivative or a salt thereof as a pesticide, and a composition and use thereof. The compound has the structure of formul...
|
|
WO/2022/036975A1 |
A preparation method for a biapenem active ingredient, comprising: 1) dissolving crude biapenem in water to prepare an aqueous solution; 2) adding activated carbon, stirring for decolorization, filtering, and cooling the filtrate for use...
|
|
WO/2022/040293A1 |
Disclosed are compounds of Formulas (I) and (II): or a salt thereof, wherein X, Y, Q1, Q2, G, R1, and R3 are defined herein. Also disclosed are methods of using such compounds as inhibitors of TLR9, and pharmaceutical compositions compri...
|
|
WO/2022/033532A1 |
Provided are an FGFR and a mutation inhibitor thereof, and a preparation method therefor and the use thereof. In particular, provided are an FGFR having a structure of formula (I) and a mutation inhibitor thereof, a preparation method th...
|
|
WO/2022/033562A1 |
The present application relates to a JAK inhibitor compound for treating severe pneumonia, specifically, to the use of a compound as represented by formula (G), or an isotope-labeled compound thereof, or an optical isomer, a geometric is...
|
|
WO/2022/034529A1 |
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; (I) wherein R1 R2, R4 and X1 are defeined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses...
|
|
WO/2022/033993A1 |
A material comprising an electron-accepting unit of formula (I), wherein Ar1 is a 5- or 6-membered aromatic or heteroaromatic ring or is absent; Ar2 is a 5- or 6-membered aromatic or heteroaromatic ring or is absent; and wherein the elec...
|
